Prolia (Denosumab) vs Evenity (Romosozumab): Side-Effect Profile Head-to-Head

Why This Is an Indirect Safety Comparison

Denosumab blocks RANK ligand and suppresses osteoclast-mediated bone resorption. Romosozumab blocks sclerostin, initially increasing bone formation while also reducing resorption. The major FREEDOM denosumab trial compared denosumab with placebo 1. The FRAME romosozumab trial also used placebo during its first year 2, while ARCH compared a romosozumab-to-alendronate sequence with alendronate alone 3.

Those studies differed in eligibility criteria, baseline fracture risk, comparator, follow-up, and event collection. Their percentages should not be treated as if the drugs had been randomized against each other. A practical comparison therefore starts with the current prescribing information and uses the trials to explain where each warning came from.

Boxed Warnings: Both Drugs Now Have One

Evenity: cardiovascular risk

The current prescribing information for Evenity says it may increase the risk of myocardial infarction, stroke, and cardiovascular death. It should not be initiated in someone who had an MI or stroke during the preceding year; other cardiovascular risk factors require an individualized benefit-risk assessment. If MI or stroke occurs during therapy, the label directs discontinuation.

The warning was driven by the imbalance in serious cardiovascular events during the first year of ARCH, where romosozumab was compared with alendronate [3]. FRAME, which compared romosozumab with placebo, did not show the same imbalance [2]. That inconsistency is one reason the true magnitude and mechanism of risk remain uncertain, but it does not negate the labeled warning.

Prolia: severe hypocalcemia in advanced kidney disease

The current prescribing information for Prolia carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, including dialysis-dependent patients. Chronic kidney disease-mineral and bone disorder further increases this risk. The label calls for evaluation for CKD-MBD before treatment and specialist supervision in this population.

This is an important correction to older comparisons that say Prolia has no boxed warning. Prolia does not require renal dose adjustment, but that does not mean it is low risk in advanced CKD.

What Happens When Treatment Stops

Prolia discontinuation requires a plan

Denosumab's antiresorptive effect reverses after dosing stops. Bone-turnover markers can rise rapidly, bone density can fall, and multiple vertebral fractures have been reported. The European Calcified Tissue Society review concluded that denosumab should not be stopped without considering alternative treatment 4. The Prolia label likewise warns of multiple vertebral fractures following discontinuation.

There is no universal calendar date or single bisphosphonate regimen that fits every patient. Timing and choice depend on the last denosumab dose, fracture risk, kidney function, prior bisphosphonate exposure, and sometimes bone-turnover testing. A missed or delayed injection should be discussed promptly with the treating clinician rather than managed with a generic online “bridge” schedule.

Evenity ends after 12 monthly doses

Evenity's anabolic effect wanes over time, and the FDA limits treatment to 12 monthly doses. Its label says antiresorptive therapy should be considered if osteoporosis treatment remains warranted. A randomized phase 2 extension found that bone-density gains continued when romosozumab was followed by denosumab but moved back toward pretreatment levels after placebo 5.

Switching from Prolia to Evenity is a different and less established question than following Evenity with an antiresorptive. It should not be represented as a routine substitute for the plan needed after denosumab.

Common and Serious Adverse Effects

This table summarizes labeled risks, not comparative incidence. Rare-event percentages from separate trials are not reliable proof that one product is categorically safer.

Monitoring Differences

Before either medicine, clinicians review serum calcium and conditions that predispose to hypocalcemia. Both labels call for adequate calcium and vitamin D intake. Dental and oral-health risk factors matter because both labels discuss osteonecrosis of the jaw.

For Prolia, advanced CKD changes the assessment substantially. The current label includes evaluation for CKD-MBD and intensive post-dose calcium monitoring for advanced CKD. For Evenity, recent MI or stroke and broader cardiovascular risk are central to selection; patients are also monitored for symptoms of cardiovascular events during treatment.

Neither label establishes a universal requirement that 25-hydroxyvitamin D must exceed 30 ng/mL for every patient. A vitamin D target should therefore not be presented as an FDA rule.

Does One Drug Have Better Long-Term Safety Data?

Denosumab has longer continuous-exposure data. The FREEDOM extension followed treatment for up to 10 years and reported persistently low fracture rates, continued bone-density gains, and rare skeletal safety events 6. That evidence does not make treatment “open-ended” for every patient; duration still requires periodic reassessment, and discontinuation remains a separate risk-management decision.

Romosozumab is intentionally limited to one 12-dose course, so it does not have comparable repeated-course exposure data. Its safety decision is concentrated around the cardiovascular warning, correction of hypocalcemia, and selection of the next therapy.

Choosing Between Prolia and Evenity

The decision is not simply “cardiovascular risk means Prolia” or “very low bone density means Evenity.” It should account for:

• how high and how immediate the fracture risk is;
• MI or stroke within the preceding year and other cardiovascular risk factors;
• kidney function, CKD-MBD, calcium, and vitamin D status;
• prior antiresorptive or anabolic treatment;
• the ability to receive Prolia on schedule;
• the treatment that will follow Prolia discontinuation or the 12th Evenity dose; and
• dental, hypersensitivity, and other individual risk factors.

A specialist may reasonably choose either medicine in some patients, but the rationale and transition plan should be explicit before the first dose.

A 2025 prospective cohort illustrates why that transition needs specialist planning: starting romosozumab three months after the last denosumab dose attenuated but did not eliminate the rise in the bone-resorption marker CTX, while the usual six-month transition had a larger rebound and two major osteoporotic fractures during follow-up (PMID 39888498).